Ophthalmology
Phase 1-2 Study: Safety and efficacy of EDIT-101 CRISPR-Cas9 treatment for CEP290-associated retinal degeneration – N Engl J Med
25 May, 2024 | 19:42h | UTCThis study evaluates the safety and effectiveness of EDIT-101, a CRISPR-Cas9 gene-editing therapy, in treating inherited retinal degeneration caused by CEP290 IVS26 variants. Conducted as a phase 1-2, open-label, single-ascending-dose trial, it involved 14 participants (12 adults aged 17-63 and 2 children aged 9 and 14) who received subretinal injections of EDIT-101. Treatment doses varied, with two participants at a low dose, seven at an intermediate dose, and five at a high dose. The primary safety assessment showed no serious adverse events or dose-limiting toxic effects. Notably, 64% of participants exhibited significant improvements in visual acuity, retinal sensitivity to red light, or mobility. Additionally, improvements in vision-related quality of life were documented in six participants. These promising results suggest that EDIT-101 is safe and potentially effective, warranting further investigation into CRISPR-Cas9 gene therapy for similar genetic retinal conditions.
Commentary on X:
Original Article: Gene Editing for CEP290-Associated Retinal Degeneration (BRILLIANCE) https://t.co/LgSs2RGBZv #ARVO2024 @ARVOinfo pic.twitter.com/WztX2OvzXM
— NEJM (@NEJM) May 7, 2024
Reference (link to abstract – $ for full-text):
RCT: Early patching proves more effective than extended optical treatment in pediatric amblyopia management – The Lancet
5 May, 2024 | 15:00h | UTCStudy Design and Population:
The EuPatch study was a multicenter, randomized controlled trial conducted across 30 hospitals in multiple European countries, including the UK, Greece, Austria, Germany, and Switzerland. It targeted children aged 3–8 years diagnosed with amblyopia due to anisometropia, strabismus, or both, with an interocular difference ≥0.30 logMAR in best corrected visual acuity (BCVA). Participants were divided into two groups: one underwent 18 weeks of glasses use before patching (Extended Optical Treatment, EOT), and the other just 3 weeks (early patching), each supplemented with an intensive patching regimen.
Main Findings:
Out of the 334 initially randomized participants, 317 were analyzed for the primary outcome. The early patching group demonstrated a significantly higher success rate, achieving ≤0.20 logMAR interocular difference in BCVA in 67% of cases compared to 54% in the EOT group after 12 weeks of patching (p=0.019). The median follow-up times were 42 weeks for the EOT group and 27 weeks for the early patching group, with dropout rates of 14% and 6%, respectively.
Implications for Practice:
The findings suggest that early patching is superior to EOT in the management of amblyopia in children, presenting a viable option for enhancing treatment effectiveness. This study supports the potential personalization of amblyopia treatments based on the quicker onset of patching. These results could influence future guidelines and clinical practices in pediatric ophthalmology.
Reference (link to free full-text):
Presented at ASRS Meeting | Studies link GLP-1 agonists to progression of diabetic retinopathy
11 Aug, 2023 | 15:38h | UTCStudies link GLP-1 agonists to progression of diabetic retinopathy – MDedge
RCT | No significant impact of low-dose 0.01% atropine on myopia progression in children
25 Jul, 2023 | 13:40h | UTCLow-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial – JAMA Ophthalmology (link to abstract – $ for full-text)
See also: Visual Abstract
Author Interview: Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control – JAMA
Commentary: Atropine 0.01 Percent Eye Drops Do Not Slow Myopia Progression – HealthDay
Related:
RCT | 0.01% atropine effective in reducing progression of myopia in children over 3 years
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.
RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.
RCT | Myopia control effect of repeated low-level red-light therapy in children.
Guideline | Prevention and management of childhood progressive myopia
18 Jul, 2023 | 13:35h | UTC
RCT | Intravitreal therapy for uveitic macular edema—ranibizumab versus methotrexate versus the dexamethasone implant
29 Jun, 2023 | 13:57h | UTCIntravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant – Ophthalmology (link to abstract – $ for full-text)
SR | Anti‐vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy
29 Jun, 2023 | 13:49h | UTC
Editorial | How to become a good surgeon
22 Jun, 2023 | 15:12h | UTCHow to become a good surgeon – Advances in Ophthalmology Practice and Research
RCT | 0.01% atropine effective in reducing progression of myopia in children over 3 years
14 Jun, 2023 | 14:41h | UTCNews Release: Eye drops slow nearsightedness progression in kids – Ohio State University
See also: Visual Abstract
Related:
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.
RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.
RCT | Myopia control effect of repeated low-level red-light therapy in children.
RCT | Immediate vs. delayed sequential bilateral cataract surgery: non-inferior in safety, higher cost-effectiveness
6 Jun, 2023 | 14:41h | UTCSafety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News Release: Cataract surgery: two-sided treatment better than one-by-one approach – Maastricht University
Review | Integrating eye care in low-income and middle-income settings
6 Jun, 2023 | 14:21h | UTCIntegrating eye care in low-income and middle-income settings: a scoping review – BMJ Open
Eye disease and international travel: a critical literature review and practical recommendations
2 Jun, 2023 | 12:21h | UTC
Study finds potential glaucoma risk in patients using calcium channel blockers
1 Jun, 2023 | 11:51h | UTCCommentary: Calcium Channel Blocker Use Associated with Higher Prevalence of Glaucoma – HCP Live
RCT | Effect of repeated low-level red light on myopia prevention among children in China with premyopia
10 May, 2023 | 15:52h | UTCCommentary: Repeated Low-Level Red-Light Intervention Prevents Myopia in Children – HealthDay
Related:
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.
RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.
RCT | Myopia control effect of repeated low-level red-light therapy in children.
Commentary on Twitter
RCT: Repeated low-level red-light (RLRL) is a novel and effective intervention for myopia prevention in children with premyopia, up to 54% reduction in incident myopia within 12 months, with good user acceptability and safety. https://t.co/geMajH5ms8
— JAMA Network Open (@JAMANetworkOpen) April 26, 2023
SR | Blood pressure control for diabetic retinopathy
17 Apr, 2023 | 12:45h | UTCBlood pressure control for diabetic retinopathy – Cochrane Library
Summary: Blood pressure control for diabetic retinopathy – Cochrane Library
SR | Device‐modified trabeculectomy for glaucoma
17 Apr, 2023 | 12:46h | UTCDevice‐modified trabeculectomy for glaucoma – Cochrane Library
Summary: Device-modified trabeculectomy for glaucoma – Cochrane Library
RCT | Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of dry eye disease
11 Apr, 2023 | 14:10h | UTCCommentary: ESSENCE-2 Trial Confirms Efficacy of Cyclosporine Solution 0.1% for DED – HCP Live
Commentary on Twitter
ESSENCE-2 trial demonstrated treatment with water-free cyclosporine 0.1% (CyclASol) drops effective and tolerable through Day 29 for treating dry eye related keratitis with rapid onset of action. https://t.co/qJkef2fPTg
— JAMA Ophthalmology (@JAMAOphth) April 6, 2023
M-A | Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants
10 Apr, 2023 | 13:36h | UTC
SR | Anti‐vascular endothelial growth factor for neovascular glaucoma
10 Apr, 2023 | 13:33h | UTC
M-A | Efficacy of atropine for myopia control in children
5 Apr, 2023 | 12:45h | UTCRelated:
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.
RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.
RCT | Myopia control effect of repeated low-level red-light therapy in children.
RCT | Pulsed oral azithromycin vs. 6-week oral doxycycline for moderate to severe meibomian gland dysfunction
31 Mar, 2023 | 13:33h | UTCPulsed Oral Azithromycin vs 6-Week Oral Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: A Randomized Clinical Trial – JAMA Ophthalmology (link to abstract – $ for full-text)
Commentary: 3-Week MGD treatment equivalent to 6-week course in efficacy and adverse events – Ophthalmology Times
Commentary on Twitter
A 3-week course of weekly oral azithromycin was equivalent to a 6-week course of oral doxycycline in treating moderate to severe meibomian gland dysfunction. https://t.co/nE312KxGki pic.twitter.com/xWmqYWby7j
— JAMA Ophthalmology (@JAMAOphth) March 23, 2023
SR | Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy
29 Mar, 2023 | 13:15h | UTCAnti‐vascular endothelial growth factor for proliferative diabetic retinopathy – Cochrane Library
Cohort Study | Retinal artery occlusion linked to a 7-fold higher mortality rate from CV and cerebrovascular diseases
23 Mar, 2023 | 13:04h | UTCSummary: This nationwide cohort study analyzed the incidence of retinal artery occlusion (RAO) in Korea from 2002 to 2018, along with related mortality and causes of death. The incidence of RAO was found to be 7.38 per 100,000 person-years, with a higher incidence of noncentral RAO compared to central RAO.
Patients with RAO had a mortality rate about 7 times higher than the general population, primarily due to cardiovascular or cerebrovascular diseases. The findings emphasize the need to address the risk of cardiovascular or cerebrovascular disease in patients newly diagnosed with RAO.
Invited Commentary: Long-term Management Considerations for Retinal Artery Occlusion and Cardiovascular and Cerebrovascular Mortality – JAMA Network Open
SR | Topical antibiotics modestly improve resolution of acute bacterial conjunctivitis
21 Mar, 2023 | 13:33h | UTCSummary: The Cochrane Review evaluated the benefits and potential side effects of antibiotic therapy in treating acute bacterial conjunctivitis. The authors included 21 randomized controlled trials, with a total of 8,805 participants. The trials evaluated the effectiveness of topical antibiotic treatments in the form of drops or ointments, and were heterogeneous in terms of eligibility criteria, antibiotic drug class, duration of treatment, and outcomes assessed.
The review found that antibiotics likely improved clinical cure by 26% compared with placebo, with no evidence of serious systemic side effects reported in either the antibiotic or placebo group. Fluoroquinolones were found to have fewer ocular side effects compared to non-fluoroquinolones.
Overall, the review suggests that the use of topical antibiotics may be considered to achieve better clinical and microbiologic efficacy than placebo in treating acute bacterial conjunctivitis.
Article: Antibiotics versus placebo for acute bacterial conjunctivitis – Cochrane Library
M-A | Global prevalence of diabetic retinopathy in pediatric type 2 diabetes
20 Mar, 2023 | 13:12h | UTC